Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping

Bibliographic Details
Main Authors:	Borthwick, N, Ahmed, T, Ondondo, B, Hayton, E, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T
Format:	Conference item
Published:	2013

Similar Items

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.
by: Borthwick, N, et al.
Published: (2014)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002
by: Ahmed, T, et al.
Published: (2011)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.
by: Hanke, T, et al.
Published: (1998)

Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
by: Borthwick, N, et al.
Published: (2017)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
by: Ondondo, B, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
by: Ondondo, B, et al.
Published: (2013)

The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics
by: Ondondo, B, et al.
Published: (2014)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
by: Dorrell, L, et al.
Published: (2005)

Is an HIV vaccine possible?
by: Mcmichael, A, et al.
Published: (1999)

Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
by: Nicola Borthwick, et al.
Published: (2017-01-01)

HIV vaccines 1983-2003.
by: Mcmichael, A, et al.
Published: (2003)

Comment on clinical development of candidate HIV vaccines: different problems for different vaccines.
by: McMichael, A, et al.
Published: (2014)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)

PedVACC 001 and 002: building foundations for infant HIV-1 vaccine trials against breast milk transmission of HIV-1
by: Hanke, T
Published: (2012)

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime.
by: Hanke, T, et al.
Published: (1999)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
by: Dorrell, L, et al.
Published: (2006)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.
by: Nathifa Moyo, et al.
Published: (2017-01-01)

Novel Nested Peptide Epitopes Recognized by CD4<sup>+</sup> T Cells Induced by HIV-1 Conserved-Region Vaccines
by: Nicola Borthwick, et al.
Published: (2020-01-01)

Design and tests of an HIV vaccine.
by: McMichael, A, et al.
Published: (2002)

Detection of broad functional gag-specific CD4+T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Ondondo, B, et al.
Published: (2006)

HIV T cell vaccines, the importance of clades.
by: McMichael, A, et al.
Published: (2002)

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
by: Borthwick, N, et al.
Published: (2018)

PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
by: Njuguna, I, et al.
Published: (2014)

PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.
by: Njuguna, I, et al.
Published: (2014)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
by: Hanke, T, et al.
Published: (2007)

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
by: Hanke, T, et al.
Published: (2000)

Design and pre-clinical evaluation of a universal HIV-1 vaccine.
by: Létourneau, S, et al.
Published: (2007)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
by: Yang, H, et al.
Published: (2007)